Viridian Therapeutics is a biopharmaceutical company discovering, developing, and commercializing potential best-in-class medicines for serious and rare autoimmune diseases. Its pipeline includes veligrotug, an IV anti-IGF-1R monoclonal antibody for thyroid eye disease (TED) with a BLA submitted to the FDA in October 2025; elegrobart, a subcutaneous anti-IGF-1R for TED in phase 3; VRDN-006 and VRDN-008, FcRn inhibitors for broad autoimmune indications; and a TSHR inhibitor for TED and Graves disease. The company targets validated pathways to improve efficacy, safety, and dosing convenience over existing therapies.
expected 2027-02-08
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001590750-26-000007 | EDGAR | 101K words |
| 2025-03-03 | 2024-12-31 | 0001590750-25-000004 | EDGAR | 91K words |
| 2024-02-27 | 2023-12-31 | 0001590750-24-000007 | EDGAR | 81K words |
| 2023-03-09 | 2022-12-31 | 0001590750-23-000002 | EDGAR | 72K words |
| 2022-03-11 | 2021-12-31 | 0001590750-22-000004 | EDGAR | 71K words |
| 2021-03-26 | 2020-12-31 | 0001590750-21-000029 | EDGAR | 72K words |
| 2020-03-13 | 2019-12-31 | 0001590750-20-000021 | EDGAR | 81K words |
| 2019-03-14 | 2018-12-31 | 0001590750-19-000013 | EDGAR | 92K words |
| 2018-03-15 | 2017-12-31 | 0001590750-18-000006 | EDGAR | 100K words |
| 2017-03-24 | 2016-12-31 | 0001171843-17-001747 | EDGAR | 92K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-11-04 | 2026-09-30 | 0001590750-26-000022 | EDGAR | 64K words |
| 2026-08-06 | 2026-06-30 | 0001590750-26-000018 | EDGAR | 61K words |
| 2025-11-05 | 2025-09-30 | 0001590750-25-000020 | EDGAR | 62K words |
| 2025-08-06 | 2025-06-30 | 0001590750-25-000012 | EDGAR | 59K words |
| 2025-05-06 | 2025-03-31 | 0001590750-25-000008 | EDGAR | 57K words |
| 2024-11-12 | 2024-09-30 | 0001590750-24-000023 | EDGAR | 57K words |
| 2024-08-08 | 2024-06-30 | 0001590750-24-000019 | EDGAR | 55K words |
| 2024-05-08 | 2024-03-31 | 0001590750-24-000012 | EDGAR | 53K words |
| 2023-11-13 | 2023-09-30 | 0001590750-23-000013 | EDGAR | 55K words |
| 2023-08-08 | 2023-06-30 | 0001590750-23-000008 | EDGAR | 53K words |
| 2023-05-10 | 2023-03-31 | 0001590750-23-000003 | EDGAR | 48K words |
| 2022-11-14 | 2022-09-30 | 0001590750-22-000012 | EDGAR | 51K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-11-09 | 0001193125-26-452665 | EDGAR | 2K words |
| 2026-11-04 | 0001193125-26-446200 | EDGAR | 3K words |
| 2026-08-06 | 0001193125-26-336691 | EDGAR | 3K words |
| 2026-03-30 | 0001193125-26-130433 | EDGAR | 9K words |
| 2026-02-26 | 0001193125-26-073391 | EDGAR | 3K words |
| 2025-11-05 | 0001193125-25-265711 | EDGAR | 4K words |
| 2025-10-23 | 0001193125-25-247410 | EDGAR | 27K words |
| 2025-10-21 | 0001193125-25-245206 | EDGAR | 1K words |
| 2025-10-20 | 0001193125-25-243039 | EDGAR | 2K words |
| 2025-08-06 | 0001193125-25-173983 | EDGAR | 4K words |
274 total filings indexed. 242 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001590750 |
| Ticker | VRDN |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.viridiantherapeutics.com |
| Listed | 2014-06-18 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/VRDN (~200 tokens, structured JSON with cryptographic provenance)